Development of treatment for HER2 or EGFR exon 20 insertion mutation-driven NSCLC

被引：0
|
作者：
Ninomiya, Kiichiro [1 ]
机构：
[1] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Hematol Oncol & Resp Med, Okayama, Japan
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷
关键词：
D O I：
10.1016/j.annonc.2022.05.478
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
SY20-3
引用
收藏
页码：S444 / S444
页数：1
相关论文
共 50 条
  • [1] Poziotinib in NSCLC harbouring EGFR or HER2 exon 20 insertion mutation
    Prelaj, A.
    Bottiglieri, A.
    Galli, E.
    Lo Russo, G.
    Ferrara, R.
    Galli, G.
    De Toma, A.
    Brambilla, M.
    Occhipinti, M.
    Manglaviti, S.
    Beninato, T.
    Zattarin, E.
    Apollonio, G.
    Ganzinelli, M.
    Gallucci, R.
    Di Mauro, R. M.
    de Braud, F.
    Torri, V.
    Garassino, M. C. C.
    Proto, C.
    ANNALS OF ONCOLOGY, 2021, 32 : S976 - S977
  • [2] Clinical outcomes for EGFR/HER2 exon 20 insertion-mutated NSCLC
    Li, K.
    Bosdet, I.
    Yip, S.
    Ho, C.
    Laskin, J.
    Melosky, B.
    Wang, Y.
    Sun, S.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1058 - S1059
  • [3] Poziotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: Results from the expanded access program
    Prelaj, Arsela
    Bottiglieri, Achille
    Proto, Claudia
    Lo Russo, Giuseppe
    Signorelli, Diego
    Ferrara, Roberto
    Galli, Giulia
    De Toma, Alessandro
    Viscardi, Giuseppe
    Brambilla, Marta
    Lobefaro, Riccardo
    Nichetti, Federico
    Manglaviti, Sara
    Occhipinti, Mario
    Labianca, Alice
    Ganzinelli, Monica
    Gallucci, Rosaria
    Zilembo, Nicoletta
    Greco, Gabriella Francesca
    Torri, Valter
    de Braud, Filippo
    Garassino, Marina C.
    EUROPEAN JOURNAL OF CANCER, 2021, 149 : 235 - 248
  • [4] Circulating tumor DNA (ctDNA) in HER2 exon 20 insertion mutations and responses in NSCLC HER2 exon 20 insertion treated with poziotinib
    不详
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [5] First-Line Therapy in NSCLC harbouring EGFR or HER2 Exon 20 Insertion Mutation. Hunting for the Best Candidate
    Prelaj, A.
    Bottiglieri, A.
    Lo Russo, G.
    Ferrara, R.
    Galli, G.
    De Toma, A.
    Brambilla, M.
    Occhipinti, M.
    Manglaviti, S.
    Beninato, T.
    Zattarin, E.
    Apollonio, G.
    Massa, G.
    Mazzeo, L.
    Galli, E.
    Dumitrascu, D.
    Ganzinelli, M.
    Gallucci, R.
    Di Mauro, R.
    Vitale, S.
    De Braud, F. G. M.
    Garassino, M. C.
    Proto, C.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1116 - S1117
  • [6] Poziotinib in advanced NSCLC with EGFR or HER2 exon 20 insertion mutation: Initial results from a single site expanded access program
    Prelaj, A.
    Bottiglieri, A.
    Proto, C.
    Lo Russo, G.
    Signorelli, D.
    Ferrara, R.
    Galli, G.
    De Toma, A.
    Viscardi, G.
    Brambilla, M.
    Lobefaro, R.
    Manglaviti, S.
    Occhipinti, M.
    Labianca, A.
    Gallucci, R.
    Molino, G.
    Zilembo, N.
    Greco, F. G.
    Torri, V.
    Garassino, M. C.
    ANNALS OF ONCOLOGY, 2020, 31 : S882 - S882
  • [7] Targeting HER2 or EGFR Exon 20 Insertion Mutation in Lung Cancer - A Case Series from India
    Varughese, V. J.
    Joseph, S.
    Sirohi, B.
    Raut, N.
    Mathew, A.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1117 - S1117
  • [8] Characterization of a panel of 79 PDX-derived cell lines with a focus on the EGFR exon 20 insertion mutation-driven NSCLC model LXFE 2478
    Kelter, Gerhard
    Peille, Anne-Lise
    Fehr, Jutta
    Klett, Hagen
    Maier, Armin
    Posch, Markus
    Metz, Thomas M.
    MOLECULAR CANCER THERAPEUTICS, 2019, 18 (12)
  • [9] Novel drugs targeting EGFR and HER2 exon 20 mutations in metastatic NSCLC
    Baraibar, Iosune
    Mezquita, Laura
    Gil-Bazo, Ignacio
    Planchard, David
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2020, 148
  • [10] Novel EGFR WT sparing, HER2 selective inhibitors for the treatment of HER2 exon 20 insertion driven tumors address a clear unmet medical need.
    Neumueller, Ralph A.
    Wilding, Birgit
    Scharn, Dirk
    Boese, Dietrich
    Santoro, Valeria
    Gerlach, Daniel
    Ettmayer, Peter
    Gerstberger, Thomas
    Fuchs, Julian
    Treu, Matthias
    Zahn, Stephan
    Baum, Anke
    Chetta, Paolo
    Pearson, Mark
    McConnell, Darryl B.
    Kraut, Norbert
    Solca, Flavio
    CANCER RESEARCH, 2021, 81 (13)
12345